Abstract Number: OC 08.5
Meeting: ISTH 2020 Congress
Theme: Diagnostics and OMICs » Biomarkers of Thrombosis and Hemostasis
Background: Nowadays little is known about the molecular profile of the occluding thrombus and its relationship with its origin and clinical evolution of patients with ischemic stroke (IS).
Aims: To analyze the proteomic profile of thrombi obtained by thrombectomy in IS patients, its association with the presence of specific CV risk factors, and the clinical evolution after thrombectomy.
Methods: Fifty thrombi of stroke patients with embolic or atherothrombotic origin obtained by thrombectomy were analyzed by SWATH-MS. Besides, parameters associated with increased risk of stroke were evaluated. Likewise, neurological function (NIHSS) and cerebral involvement (ASPECTS) prior to thrombectomy and the clinical status of patients at 3 months of IS were evaluated, using the modified Rankin scale (mRS).
Results: Proteomic analysis allowed the identification and quantification of 585 proteins, mainly related to primary hemostasis, integrin and kinase signaling linked to integrins, glycolysis and acute phase reactants. Comparative analyses identified four protein signatures based on predisposing factors such as hypertension, dyslipidemia, obesity and diabetics. Likewise, 15 proteins, related to immune response or cellular metabolism and involved in vascular diseases, correlated with the NIHSS and ASPECTS scales.
Interestingly, 10 altered proteins in patients with negative evolution at 3 months (mRS>2) were identified, associated with the development of stroke or brain damage, platelet aggregation, mortality and arterial thrombosis. Among them, gelsolin (GSN) and Integrin-linked kinase (ILK) were found increased in the serum of patients with mRS>2 at 3 months, suggesting that they could be considered circulating biomarkers of negative clinical evolution.
Conclusions: The use of the SWATH-MS technique has allowed the identification of numerous proteins in the thrombi and the characterization of protein signatures as potential biomarkers to determine their origin and define a therapeutic strategy after IS.
Supported by Junta de Andalucía (PAIDI CTS620).
To cite this abstract in AMA style:
Lopez-Pedrera C, Ibañez-Costa A, Perez-Sanchez C, Luque-Tevar M, Patiño-Trives AM, Abalos-Aguilera MDC, Barbarroja N, Ochoa-Sepulveda JJ, Delgado-Acosta F, Oteros-Fernandez R, Velasco F. Characterization of the Protein Profile in Thrombi of Patients with Ischemic Stroke and Identification of Potential Biomarkers as Predictors of Negative Clinical Evolution [abstract]. Res Pract Thromb Haemost. 2020; 4 (Suppl 1). https://abstracts.isth.org/abstract/characterization-of-the-protein-profile-in-thrombi-of-patients-with-ischemic-stroke-and-identification-of-potential-biomarkers-as-predictors-of-negative-clinical-evolution/. Accessed March 21, 2024.« Back to ISTH 2020 Congress
ISTH Congress Abstracts - https://abstracts.isth.org/abstract/characterization-of-the-protein-profile-in-thrombi-of-patients-with-ischemic-stroke-and-identification-of-potential-biomarkers-as-predictors-of-negative-clinical-evolution/